Avis Budget Group, Inc. logo CAR - Avis Budget Group, Inc.

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY 0
BUY 2
HOLD 8
SELL 3
STRONG
SELL 0
| PRICE TARGET: $129.17 DETAILS
HIGH: $160.00
LOW: $95.00
MEDIAN: $132.50
CONSENSUS: $129.17
UPSIDE: 25.62%

Stock News

Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma

Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma

First clinical evaluation of Xenetic's systemic DNase technology as an adjunct to CAR T-cell therapy in an investigator-initiated study conducted at Tel Aviv Sourasky University Medical Center Initial efficacy data expected in Q2 2027 FRAMINGHAM, MA / ACCESS Newswire / October 15, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its collaboration partner, PeriNess Ltd. ("PeriNess"), has informed the Company that the first patient has been dosed in an investigator-initiated clinical study evaluating systemic recombinant human DNase in combination with anti-CD19 CAR T-cell therapy in patients with large B-cell lymphoma ("LBCL") at the Tel Aviv Sourasky University Medical Center ("Ichilov Center") in Israel.

Oct 15, 2026 04:46 AM • accessnewswire.com
Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy

Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy

LB2501 is an off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells directly within the patient after a single infusion, making it the first known dual-targeting in vivo CAR-T therapy to receive FDA IND clearance  IND clearance supports planned U.S. Phase 1/2 study and advances Legend Biotech's in vivo cell engineering platform BRIDGEWATER, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for LB2501, an investigational in vivo CAR-T therapy designed to generate CD19/CD20 dual-targeting chimeric antigen receptor T (CAR-T) cells directly within the patient, for the treatment of relapsed or refractory B-cell malignancies, including B-cell non-Hodgkin lymphoma.

Oct 15, 2026 04:00 AM • globenewswire.com
Lakefront Announces Sale of Preclinical CAR-T Programs to Armed Cell Therapeutics

Lakefront Announces Sale of Preclinical CAR-T Programs to Armed Cell Therapeutics

Previously announced wind-down of the legacy cell therapy activities is substantially complete  Mechelen, Belgium; October 14, 2026, 22.01 CEST; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that it has completed the sale of its early-stage cell therapy pipeline to Armed Cell Therapeutics BV, a Belgium-based biotechnology company developing next-generation armed CAR-T therapies for cancer and formed by experienced executives Paul Stoffels, John Mellors and Peter Verhaeghe. The preclinical program is based on technology originated from, and research undertaken by AboundBio, which was acquired by Lakefront NV (previously Galapagos NV) in 2022.

Oct 14, 2026 12:01 PM • globenewswire.com
Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference

Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference

Dr. Jose Conejo-Garcia will speak on immunotherapy for ovarian cancer at the November 2–3 conference SAN JOSE, Calif., Oct. 13, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Jose Conejo-Garcia, MD, PhD, inventor of Anixa's CAR-T therapy for ovarian cancer, will deliver a keynote presentation at the 2026 Ovarian Cancer Midwest Focus Conference.

Oct 13, 2026 04:40 AM • prnewswire.com
Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial

First patient in current dose cohort exhibited no progression of her cancer three months aftertreatment Multiple patients have survived more than one year, including one beyond two years No dose-limiting toxicities observed to date SAN JOSE, Calif., Oct. 5, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that a patient in its ongoing Phase 1, dose-escalating, clinical trial evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer, exhibited stable disease 90 days after treatment.

Oct 05, 2026 04:15 AM • prnewswire.com
Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma

Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma

Annual program will award funding to early-career healthcare professionals advancing research, education, and innovation in multiple myeloma BRIDGEWATER, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the launch of its inaugural Emerging Leadership & Innovation in Cell Therapy Excellence (ELITE) Program, an annual grant initiative designed to recognize and support early-career healthcare professionals advancing novel cell therapy approaches for the treatment of multiple myeloma.

Oct 01, 2026 05:00 AM • globenewswire.com
Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial

Multiple Patients Surviving More Than One Year, Including One Beyond Two Years, With No Dose-Limiting Toxicities Observed to Date Patients in Cohort 5 Will Receive 1×10⁷ CAR-Positive Cells/kg Following Lymphodepletion SAN JOSE, Calif., Oct. 1, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the second patient has been treated in the fifth cohort of its ongoing Phase 1, dose-escalating, clinical trial (ClinicalTrials.gov NCT05316129) evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer.

Oct 01, 2026 04:35 AM • prnewswire.com
Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored' CAR T Therapy for Ovarian Cancer

Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored' CAR T Therapy for Ovarian Cancer

Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials First patient treated in new clinical trial underway at Roswell Park Treatment is designed to avoid pre-infusion chemotherapy and its side effects GB-5267 targets MUC16, a biomarker over-expressed in +80% of ovarian tumors BUFFALO, N.Y. and SOMERVILLE, Mass.

Oct 01, 2026 03:00 AM • globenewswire.com
Pomerantz Law Firm Announces the Filing of a Class Action on Behalf of Investors in Avis Budget Group, Inc. – CAR

Pomerantz Law Firm Announces the Filing of a Class Action on Behalf of Investors in Avis Budget Group, Inc. – CAR

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed on behalf of investors in Avis Budget Group, Inc. (“Avis” or the “Company”) (NASDAQ: CAR).   The class action, filed in the United States District Court for the Middle District of Florida, and docketed under 26-cv-02275, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Avis securities (including those who bought Avis common stock to cover a short position) between February 20, 2025 and April 21, 2026, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 9(a) and 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against Pentwater Capital Management LP (“Pentwater”) and its Founder, Chief Executive Officer (“CEO”), and Chief Investment Officer Matthew Halbower (“Halbower”).

Sep 29, 2026 12:25 PM • globenewswire.com (Hide legal announcements)
AVIS DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Avis Budget Group, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action Against Pentwater Capital Management LP - CAR

AVIS DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Avis Budget Group, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action Against Pentwater Capital Management LP - CAR

New York, New York--(Newsfile Corp. - September 29, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Avis Budget Group, Inc. (NASDAQ: CAR), including those who bought Avis common stock to cover a short position, between February 20, 2025 and April 21, 2026, inclusive (the "Class Period"), of the important September 29, 2026 lead plaintiff deadline. SO WHAT: If you purchased Avis securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Sep 29, 2026 12:17 PM • newsfilecorp.com (Hide legal announcements)
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 29, 2026 in Pentwater Capital Management LP Lawsuit - CAR

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 29, 2026 in Pentwater Capital Management LP Lawsuit - CAR

A securities class action alleges that Pentwater Capital Management LP and its CEO drove Avis Budget Group shares up more than 400% before dumping 4.3 million shares over two trading days, and this release maps the sequence of dated events investors are being asked to examine. A securities class action alleges that Pentwater Capital Management LP and its CEO drove Avis Budget Group shares up more than 400% before dumping 4.3 million shares over two trading days, and this release maps the sequence of dated events investors are being asked to examine.

Sep 29, 2026 06:22 AM • globenewswire.com (Hide legal announcements)
Avis Budget Deadline: CAR Investors Have Opportunity to Lead Avis Budget Group, Inc. Securities Fraud Lawsuit Against Pentwater Capital Management LP

Avis Budget Deadline: CAR Investors Have Opportunity to Lead Avis Budget Group, Inc. Securities Fraud Lawsuit Against Pentwater Capital Management LP

NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Avis Budget Group, Inc. (NASDAQ: CAR), including those who bought Avis common stock to cover a short position, between February 20, 2025 and April 21, 2026, inclusive (the "Class Period"), of the important September 29, 2026 lead plaintiff deadline.

Sep 28, 2026 05:16 PM • prnewswire.com (Hide legal announcements)
AVIS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Avis Budget Group, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action Against Pentwater Capital Management LP - CAR

AVIS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Avis Budget Group, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action Against Pentwater Capital Management LP - CAR

New York, New York--(Newsfile Corp. - September 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Avis Budget Group, Inc. (NASDAQ: CAR), including those who bought Avis common stock to cover a short position, between February 20, 2025 and April 21, 2026, inclusive (the "Class Period"), of the important September 29, 2026 lead plaintiff deadline. SO WHAT: If you purchased Avis securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Sep 28, 2026 12:11 PM • newsfilecorp.com (Hide legal announcements)
Bronstein, Gewirtz & Grossman LLC Urges Avis Budget Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman LLC Urges Avis Budget Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against against Pentwater Capital Management LP (“Pentwater”) and its Founder, Chief Executive Officer (“CEO”), and Chief Investment Officer Matthew Halbower (“Halbower”) and on behalf of investors in Avis Budget Group, Inc. (NASDAQ: CAR).

Sep 28, 2026 08:00 AM • globenewswire.com (Hide legal announcements)
CAR FINAL DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Avis Budget Group, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action Against Pentwater Capital Management LP - CAR

CAR FINAL DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Avis Budget Group, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action Against Pentwater Capital Management LP - CAR

NEW YORK, Sept. 27, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Avis Budget Group, Inc. (NASDAQ: CAR), including those who bought Avis common stock to cover a short position, between February 20, 2025 and April 21, 2026, inclusive (the “Class Period”), of the important September 29, 2026 lead plaintiff deadline.

Sep 27, 2026 05:59 PM • globenewswire.com (Hide legal announcements)
CAR FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Avis Budget Group, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action Against Pentwater Capital Management LP - CAR

CAR FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Avis Budget Group, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action Against Pentwater Capital Management LP - CAR

New York, New York--(Newsfile Corp. - September 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Avis Budget Group, Inc. (NASDAQ: CAR), including those who bought Avis common stock to cover a short position, between February 20, 2025 and April 21, 2026, inclusive (the "Class Period"), of the important September 29, 2026 lead plaintiff deadline. SO WHAT: If you purchased Avis securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Sep 26, 2026 06:08 PM • newsfilecorp.com (Hide legal announcements)
CAR FINAL DEADLINE: ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages Avis Budget Group, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action Against Pentwater Capital Management LP - CAR

CAR FINAL DEADLINE: ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages Avis Budget Group, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action Against Pentwater Capital Management LP - CAR

New York, New York--(Newsfile Corp. - September 25, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Avis Budget Group, Inc. (NASDAQ: CAR), including those who bought Avis common stock to cover a short position, between February 20, 2025 and April 21, 2026, inclusive (the "Class Period"), of the important September 29, 2026 lead plaintiff deadline. SO WHAT: If you purchased Avis securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Sep 25, 2026 06:01 PM • newsfilecorp.com (Hide legal announcements)

Price Targets